BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary...

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

The phase III REACH study evaluating Fulcrum's losmapimod for treating facioscapulohumeral muscular dystrophy fails to meet the primary endpoint.

Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability...

The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy...

The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy...

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...